CNAM
CPRX

Campbell Newman Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Campbell Newman Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29M Buy
92,476
+1,559
+2% +$37.1K 0.19% 57
2025
Q4 		$2.12M Sell
90,917
-3,449
-4% -$76.8K 0.16% 63
2025
Q3 		$1.86M Buy
94,366
+398
+0.4% +$8.19K 0.14% 73
2025
Q2 		$2.04M Buy
93,968
+6,233
+7% +$147K 0.16% 66
2025
Q1 		$2.13M Sell
87,735
-390
-0.4% -$8.78K 0.18% 60
2024
Q4 		$1.84M Sell
88,125
-218
-0.2% -$4.68K 0.15% 68
2024
Q3 		$1.76M Sell
88,343
-1,440
-2% -$26.7K 0.13% 74
2024
Q2 		$1.39M Buy
89,783
+311
+0.3% +$4.84K 0.11% 79
2024
Q1 		$1.43M Buy
+89,472
New +$1.35M 0.12% 78

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Campbell Newman Asset Management's CPRX Position: Q1 2026 in Review

Campbell Newman Asset Management increased its Catalyst Pharmaceutical (CPRX) stake by 1.7% in Q1 2026, buying an estimated $37.1K and bringing the position to 92,476 shares worth $2.29M. The position accounts for 0.19% of the portfolio, ranked #57.

Campbell Newman Asset Management first reported a position in CPRX in Q1 2024 and has held it in 9 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Campbell Newman Asset Management held 92,476 shares of Catalyst Pharmaceutical worth $2.29M as of Q1 2026.
  • Campbell Newman Asset Management bought 1,559 Catalyst Pharmaceutical shares in Q1 2026, an estimated $37.1K.
  • Catalyst Pharmaceutical made up 0.19% of Campbell Newman Asset Management's portfolio in Q1 2026, its #57 holding.
  • Campbell Newman Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 9 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Campbell Newman Asset Management's 13F filing for Q1 2026, filed 16 Apr 2026.